Search results for "lobo"

showing 10 items of 83 documents

Globorotalia truncatulinoides in Central - Western Mediterranean Sea during the Little Ice Age

2020

Abstract Globorotalia truncatulinoides oscillations have been recorded from different marine sediment cores collected in the central and western Mediterranean Sea. The abundances of this species over the last 500 yrs. demonstrates its potential value as bio-indicator of particular oceanographic condition during the Maunder Minimum (MM) event of the Little Ice Age (LIA). The comparison between the G. truncatulinoides abundance patterns of the Balearic Basin, central and south Tyrrhenian Sea and central and eastern Sicily Channel allows to highlight a similar response of this species during the MM event in the central-western Mediterranean Sea. The ecological meanings of this species and its …

010506 paleontology010504 meteorology & atmospheric sciencesMaunder MinimumMixed layerGloborotalia trucatulinoidesStructural basinOceanography01 natural sciencesMediterranean seaGloborotalia truncatulinoides Little Ice Age Maunder minimum Mediterranean Sea Mixed layerAbundance (ecology)Mixed layer14. Life underwater0105 earth and related environmental sciencesgeographygeography.geographical_feature_categoryAdvectionPaleontologySedimentSettore GEO/01 - Paleontologia E PaleoecologiaGloborotalia truncatulinoidesOceanographyProductivity (ecology)13. Climate actionMediterranean seaLittle Ice AgeGloborotalia truncatulinoides; Maunder minimum; Little Ice AgeGeologyChannel (geography)
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Dominant variants in the splicing factor PUF60 cause a recognizable syndrome with intellectual disability, heart defects and short stature

2016

Item does not contain fulltext Verheij syndrome, also called 8q24.3 microdeletion syndrome, is a rare condition characterized by ante- and postnatal growth retardation, microcephaly, vertebral anomalies, joint laxity/dislocation, developmental delay (DD), cardiac and renal defects and dysmorphic features. Recently, PUF60 (Poly-U Binding Splicing Factor 60 kDa), which encodes a component of the spliceosome, has been discussed as the best candidate gene for the Verheij syndrome phenotype, regarding the cardiac and short stature phenotype. To date, only one patient has been reported with a de novo variant in PUF60 that probably affects function (c.505C>T leading to p.(His169Tyr)) associated wi…

0301 basic medicineMaleMESH: Heart Defects Congenital / physiopathologyMicrocephalyPathologyMESH: Heart Defects Congenital / geneticsMESH: Exome / genetics030105 genetics & heredityMESH: RNA Splicing / geneticsMicrophthalmia[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMESH: ChildExomeMESH: RNA Splicing Factors / geneticsChildFrameshift MutationMESH: High-Throughput Nucleotide SequencingGenetics (clinical)Exome sequencingColobomaMESH: Frameshift MutationHigh-Throughput Nucleotide SequencingMicrodeletion syndromeMicrocephaly Verheij syndrome PUF60ChemistryPhenotypeChild PreschoolDISEASESMicrocephalyMedical geneticsFemaleRNA Splicing Factorsmedicine.symptomChromosome DeletionChromosomes Human Pair 8MESH: Dwarfism / genetics*Heart Defects Congenitalmedicine.medical_specialtyGENESAdolescentRNA SplicingMESH: Chromosome DeletionDwarfismBiologyMESH: PhenotypeShort statureArticlePUF6003 medical and health sciencesInternal medicineIntellectual Disability[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyGeneticsmedicineHumansCraniofacialBiologyMESH: AdolescentNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]MESH: HumansMESH: Child Preschoolmedicine.diseaseMESH: Repressor Proteins / geneticsMESH: MaleRepressor Proteins030104 developmental biologyEndocrinologyMESH: Chromosomes Human Pair 8 / geneticsMESH: Dwarfism / physiopathologyMESH: Intellectual Disability / physiopathologyHuman medicineMESH: Intellectual Disability / geneticsVerheij syndromeMESH: Female[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

2019

Abstract Background Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. Methods In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-w…

0301 basic medicineMalemedicine.medical_specialtyAbdominal painAdolescentEndocrinology Diabetes and MetabolismGlobotriaosylceramideUrologyRenal function030105 genetics & heredityBiochemistrylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRandomized controlled triallawBiopsyGeneticsmedicineHumansEnzyme Replacement TherapyChildMolecular BiologySkinKidneymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseIsoenzymesmedicine.anatomical_structureTreatment OutcomechemistryChild Preschoolalpha-GalactosidaseFabry Diseasemedicine.symptombusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group

2017

Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globotriaosylceramide (Gb3). Although the introduction of Enzyme Replacement Therapy (ERT) resulted in a variety of clinical benefits, life-long intravenous (IV) treatment with ERT with an every other week schedule, may interfere with daily life activities and impact on QoL. We report here a multicentric, observational, longitudinal data analysis on a large cohort of 85 Italian FD patients (45 males, 40 females) from 11 out of 20 Italian regions, who received a cumulative number of 4269 home infu…

0301 basic medicinePediatricsmedicine.medical_specialtyQoLGlobotriaosylceramide03 medical and health scienceschemistry.chemical_compoundCollaborative group0302 clinical medicineEndocrinologyDisease severityGeneticGeneticsMedicine030212 general & internal medicinelcsh:QH301-705.5Molecular Biologylcsh:R5-920Fabry diseasebusiness.industrySettore BIO/14Home treatmentEnzyme replacement therapyAdherence; Enzyme replacement therapy; Fabry disease; Home treatment; QoLmedicine.diseaseFabry disease3. Good health030104 developmental biologylcsh:Biology (General)chemistryAdherenceEnzyme replacement therapyCohortarticle;congenital malformation; Fabry disease; enzyme replacement therapy; home treatment ; adherence; QoLObservational studyHome treatmentlcsh:Medicine (General)businessResearch Paper
researchProduct

Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system.

2018

Contrary to the mainstream blood group systems, P1PK continues to puzzle and generate controversies over its molecular background. The P1PK system comprises three glycosphingolipid antigens: Pk, P1 and NOR, all synthesised by a glycosyltransferase called Gb3/CD77 synthase. The Pk antigen is present in most individuals, whereas P1 frequency is lesser and varies regionally, thus underlying two common phenotypes: P1, if the P1 antigen is present, and P2, when P1 is absent. Null and NOR phenotypes are extremely rare. To date, several single nucleotide polymorphisms (SNPs) have been proposed to predict the P1/P2 status, but it has not been clear how important they are in general and in relation …

0301 basic medicinePhysiologyCell Membraneslcsh:MedicineArtificial Gene Amplification and ExtensionBiochemistryPolymerase Chain Reactionchemistry.chemical_compoundSpectrum Analysis TechniquesTranscription (biology)GenotypeMedicine and Health Scienceslcsh:ScienceGeneticsMultidisciplinaryGlobosidesHomozygoteGlycosphingolipidFlow CytometryGalactosyltransferasesPhenotypeLipidsBody FluidsElectrophysiologyCholesterolBloodPhenotypeSpectrophotometryBlood Group AntigensCytophotometryAnatomyCellular Structures and OrganellesResearch ArticleGenotypeSingle-nucleotide polymorphismBiologyResearch and Analysis MethodsReal-Time Polymerase Chain ReactionMembrane PotentialPolymorphism Single NucleotideAntibodiesGlycosphingolipids03 medical and health sciencesAntigenGlycosyltransferaseHumansMolecular Biology TechniquesMolecular BiologyBlood typeSphingolipidslcsh:RBiology and Life SciencesCell Biology030104 developmental biologychemistrybiology.proteinlcsh:QBlood GroupsPLoS ONE
researchProduct

Oxidative stress biomarkers in Fabry disease: is there a room for them?

2020

Abstract Background Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression. Methods We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls. Results AOPP levels were higher in patients than in controls (p < 0.00001) and patients presented decreased levels of…

0301 basic medicinemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentGlobotriaosylceramideOxidative phosphorylationDiseasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelysoGb3Internal medicinemedicineHumansFabry diseaseOriginal Communicationbusiness.industryBiomarkermedicine.diseaseFabry diseasePathophysiologyOxidative Stress030104 developmental biologyEndocrinologyNeurologychemistryAdvanced oxidation protein productsalpha-GalactosidaseMutationNeurology (clinical)businessBiomarkers030217 neurology & neurosurgeryOxidative stressJournal of Neurology
researchProduct

Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales

2014

“Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales” es la primera parte de un trabajo de documentación para un capítulo de “La democracia en la Comunidad Valenciana. Partidos, elites políticas, elecciones y programas políticos”. “Mujer, poder político y democracia paritaria”. Se recoge el papel de la mujer en la vida política de la Comunidad Valenciana en la democracia actual, desde 1977. Es documentación sin elaborar, pero que aporta datos de la presencia de la mujer en las instituciones, partidos y sindicatos. Cuando este completa será una parte de la investigación referida, y de la que ya hay dos publicacion…

:CIENCIA POLÍTICA [UNESCO]UNESCO::HISTORIAUNESCO::CIENCIA POLÍTICA:HISTORIA [UNESCO]Dolores Ibarruri Pasionaria. Josefina López Sanmartín PCE. Ciprià Císcar Casabán. Pilar Brabo Castells. Palmira Pla Pechoviento. Adela Pla Pastor. democracia paritaria. Asunción Cruañes Molina. Carmen Alborch Bataller. Maria A. Armengol Criado. Clementina Rodenas Villena. Rita Barberá Nolla. Irma Simón Calvo. Teresa Sempere Jaén. Ofelia Soler Nomdedeu. María C. Díaz Villanueva. María Carmen Pardo Raga. Eva María Amador Guillén. Presentación Urán González. María Isabel Díez de la Lastra Barbadillo. Elena Irene Martín Crevillén. María Enriqueta Seller Roca de Togores. María Carmen Pardo Raga. Eva María Amador Guillén. María J. Mora Devis. Olga Mulet Torres. Margarita Pin Arboledas. Juana Serna Masiá. Leire Pajín Iraola. Rosa M. Peris Cervera. Amparo Ferrando. Carmen Arjona. María I. España Moya. Federica Montseny Mañé. Matilde Fernández Sanz. Rosa Conde Gutiérrez del Álamo. María de los Ángeles Amador Millán. Cristina Alberdi Alonso. Margarita Mariscal de Gante Mirón. Esperanza Aguirre Gil de Biedma. Loyola de Palacio del Valle-Lersundi. Isabel Tocino Biscarolasaga. Pilar del Castillo Vera. Celia Villalobos Talero. Anna María Birulés Beltrán Ana Pastor. Ana de Palacio del Valle-Lersundi. Elvira Rodríguez Herrero. Julia García-Valdecasas. Ana Mª Castellanos Vilar. Elena Mª Martín Yánez. Paloma Gómez Osorio. Concepción Pérez Morales. Francisca Benabent Fuentes. Carmen Monzó Juan. Rosa Mª Morte Julián. Gloria Marcos Martí. Lourdes Alonso Belza. Pilar Pedraza. María García-Lliberos Sánchez-Robles. Blanca Blanquer. Dolors Giner Duran. Teresa Fluvía Rodríguez. Trinidad Simó. Emilia Noguera. Hortensia Moriones Almaraz. Carolina García Mahiques. Hortensia Moriones Almaraz. Juana Serna Maciá. Lourdes Alonso Belza. Inmaculada Rodríguez-Piñero Fdez. Carmen Macián Armengod. Carmen Moya García. María José López Rodenas. María Juan Millet. Alicia de Miguel García. Ana Encabo Balbín. Ana Michavila Nuñez. Isabel Villalonga Campos. Carmen Dolz Adell. Eva Maria Amador Guillen. Alida C. Mas Taberner. Dora Ibars Sancho. Amparo Koninckx Frasquet. Blanca Martínez de Vallejo Fuster. Consuelo Císcar Casabán. Auxiliadora Hernández Miñana. Silvia Caballer Almela. Gemma Amor Pérez. Emma Iranzo Martín. Cristina Serrano Mateo. Cristina Santamarina Ciurana
researchProduct

Globorotalia truncatulinoides in the Mediterranean Basin during the Middle–Late Holocene: Bio-Chronological and Oceanographic Indicator

2022

The planktonic foraminiferal species Globorotalia truncatulinoides is widely used as a biostratigraphic proxy for the Quaternary in the Mediterranean region. High-resolution quantitative studies performed on sediment cores collected in the central and western Mediterranean Sea evidence a significant abundance of G. truncatulinoides during the Middle Holocene. The robust chronological frame allows us to date this bio-event to 4.8–4.4 ka Before Present (BP), very close to the base of the Meghalayan stage (4.2 ka BP). As a consequence, we propose that G. truncatulinoides can be considered a potential marker for the Middle–Late Holocene chronological subdivision. G. truncatulinoides is a deep-d…

<i>Globorotalia truncatulinoides</i>; Meghalayan stage; 4.2 event; vertical mixing; Mediterranean SeaGloborotalia truncatulinoides4.2 eventGloborotalia truncatulinoides; Meghalayan stage; 4.2 event; vertical mixing; Mediterranean Seavertical mixingMediterranean SeaGeneral Earth and Planetary SciencesMeghalayan stageSettore GEO/01 - Paleontologia E Paleoecologia
researchProduct

Soluble-protein and antigenic heterogeneity in axenic Blastocystis hominis isolates: pathogenic implications.

1999

The protein profile and the antigenic cross-reactivity of 18 axenic isolates of Blastocystis hominis obtained from symptomatic patients with chronic diarrhea (14 isolates) showing no evidence of parasitic etiology and from patients with acute diarrhea attributable in 2 cases to Salmonella spp. were analyzed. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of soluble proteins showed the existence of a common profile composed of 31 bands, with molecular weights ranging between 24 and >200 kDa, and minor differences in the proteins of 149, 118, 106, 50, 48, 47, and 30 kDa. These differences allowed us to classify the strains into three related patterns (I–III). In an indirect immunof…

AdultDiarrheaSalmonellaImmunodiffusionProtozoan ProteinsAntigens ProtozoanHIV InfectionsBlastocystis InfectionsBiologyLoboseaCross Reactionsmedicine.disease_causeMicrobiologyAntigenmedicineAnimalsHumansBlastocystis hominisAxenicGel electrophoresisBlastocystisGeneral VeterinaryGeneral Medicinebiology.organism_classificationVirologyMolecular WeightDiarrheaInfectious DiseasesInsect ScienceAcute DiseaseChronic DiseaseSalmonella InfectionsProtozoaParasitologyElectrophoresis Polyacrylamide Gelmedicine.symptomParasitology research
researchProduct